Actualités et vidéos - CHEMOCENTRYX INC.

Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, is investigating whether certain directors and officers of ChemoCentryx, Inc. (“ChemoCentryx”) (NASDAQ: CCXI) breached their fiduciary duties to ChemoCentryx and its shareholders. If you are a ChemoCentryx shareholder, you may contact attorney Joe Pettigrew for additional information toll-free at 844-818-6982 or [email protected] . Scott+Scott is investigating...

Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, is investigating whether certain directors and officers of ChemoCentryx, Inc. (“ChemoCentryx”) (NASDAQ: CCXI) breached their fiduciary duties to ChemoCentryx and its shareholders. If you are a ChemoCentryx shareholder, you may contact attorney Joe Pettigrew for additional information toll-free at 844-818-6982 or [email protected] . Scott+Scott is investigating...

Shareholder Alert - The M&A Class Action Firm Announces the Investigation of ChemoCentryx, Inc. - CCXI PR Newswire NEW YORK, Aug. 9, 2022 NEW YORK , Aug. 9, 2022 /PRNewswire/ -- Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City , is investigating...

SHAREHOLDER ALERT: Weiss Law Investigates ChemoCentryx, Inc PR Newswire NEW YORK, Aug. 4, 2022 NEW YORK , Aug. 4, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of ChemoCentryx, Inc. ("ChemoCentryx" or the "Company") (NASDAQ: CCXI), in connection with the proposed acquisition of the Company by Amgen Inc. (NASDAQ: AMGN).Under the terms of the merger agreement, the Company's shareholders will receive $52.00...

Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of ChemoCentryx, Inc. (NASDAQ: CCXI) to Amgen Inc. for $52.00 per share in cash is fair to ChemoCentryx shareholders. Halper Sadeh encourages ChemoCentryx shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected] . The investigation concerns whether ChemoCentryx and its board of...

Thinking about buying stock in Draftkings, ChemoCentryx, Opendoor Technologies, 1life Healthcare, or Enservco Corp? PR Newswire NEW YORK, May 6, 2022 NEW YORK , May 6, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DKNG, CCXI, OPEN, ONEM , and ENSV. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. DKNG:...

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into ChemoCentryx, Inc. (NasdaqGS: CCXI). On May 4, 2021, the U.S. Food and Drug Administration (the “FDA”) issued briefing documents regarding the New Drug Application for the Company’s drug candidate, avacopan, In the disclosure, the FDA noted that “[c]omplexities of the study design…raise questions about...

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into ChemoCentryx, Inc. (NasdaqGS: CCXI). On May 4, 2021, the U.S. Food and Drug Administration (the “FDA”) issued briefing documents regarding the New Drug Application for the Company’s drug candidate, avacopan, In the disclosure, the FDA noted that “[c]omplexities of the study design…raise questions about...

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in ChemoCentryx, Inc. (“ChemoCentryx” or “the Company”) (NASDAQ: CCXI ) for potential breaches of fiduciary duty on the part of its directors and management. If you are a shareholder who has held shares of ChemoCentryx since before November 2019 , click here to participate . We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century...

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in ChemoCentryx, Inc. (“ChemoCentryx” or “the Company”) (NASDAQ: CCXI ) for potential breaches of fiduciary duty on the part of its directors and management. If you are a shareholder who has held shares of ChemoCentryx since before November 2019 , click here to participate . We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century...

CHEMOCENTRYX INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of ChemoCentryx, Inc. - CCXI PR Newswire NEW ORLEANS, Feb. 18, 2022 NEW ORLEANS , Feb. 18, 2022 /PRNewswire/ -- Former Attorney General of Louisiana , Charles C. Foti, Jr., Esq. , a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into ChemoCentryx, Inc. (NasdaqGS: CCXI). On May 4, 2021 , the U.S....

Shareholder rights law firm Robbins LLP is investigating ChemoCentryx, Inc. (NASDAQ: CCXI) to determine whether certain ChemoCentryx officers and directors violated securities laws and breached fiduciary duties to shareholders. ChemoCentryx is a biopharmaceutical company that develops and commercializes new medications targeting inflammatory disorders, autoimmune diseases, and cancer. ChemoCentryx's lead drug candidate is avacopan, which the Company describes as a "potential first-in-class,...

Thinking about buying stock in ChemoCentryx, Sundial Growers, Momentive Global, Vaxart, or Biomerica? PR Newswire NEW YORK, Oct. 8, 2021 NEW YORK , Oct. 8, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CCXI, SNDL, MNTV, VXRT, and BMRA. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. CCXI:...

(CCXI Long-Term Investor Alert: Did You Acquire ChemoCentryx Before November 26, 2019? Should Management be Held Accountable for Investors Losses? PR Newswire SAN DIEGO, July 7, 2021 SAN DIEGO , July 7, 2021 /PRNewswire/ -- Johnson Fistel , LLP is investigating potential claims on behalf of ChemoCentryx Inc. ("ChemoCentryx" or the "Company") ( NASDAQ: CCXI) against certain of its current and former officers and directors. Recently a class action lawsuit was filed in federal court against the...

Thinking about buying stock in Clover Health, Transocean, ChemoCentryx, BioHiTech Global, or Welbilt? PR Newswire NEW YORK, July 6, 2021 NEW YORK , July 6, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CLOV, RIG, CCXI, BHTG, and WBT. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. CLOV:...

CHEMOCENTRYX 24 HOUR DEADLINE ALERT: FORMER LOUISIANA ATTORNEY GENERAL AND KAHN SWICK & FOTI, LLC REMIND INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Deadline in Class Action Lawsuits Against ChemoCentryx, Inc. - CCXI PR Newswire NEW ORLEANS, July 5, 2021 NEW ORLEANS , July 5, 2021 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana , Charles C. Foti, Jr. , remind investors that they have only until July 6, 2021 to file lead plaintiff...

Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have only until July 6, 2021 to file lead plaintiff applications in securities class action lawsuits against ChemoCentryx, Inc. (NasdaqGS: CCXI), if they purchased the Company’s shares between November 26, 2019 and May 6, 2021, inclusive (the “Class Period”). These actions are pending in the United States District Court for the Northern District of...

Thinking about buying stock in Iterum Therapeutics, Kymera Therapeutics, Senseonics, Avrobio, or ChemoCentryx? PR Newswire NEW YORK, June 28, 2021 NEW YORK , June 28, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ITRM, KYMR, SENS, AVRO, and CCXI. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. ITRM:...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ChemoCentryx, Inc. - CCXI PR Newswire NEW YORK, June 22, 2021 NEW YORK , June 22, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ChemoCentryx, Inc. ("ChemoCentryx" or the "Company") (NASDAQ: CCXI). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The investigation concerns whether ChemoCentryx and certain of its...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ChemoCentryx, Inc. - CCXI PR Newswire NEW YORK, June 16, 2021 NEW YORK , June 16, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ChemoCentryx, Inc. ("ChemoCentryx" or the "Company") (NASDAQ: CCXI). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The investigation concerns whether ChemoCentryx and certain of its...